Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis.

ABSTRACT:

Background

Tegoprazan is a novel potassium-competitive acid blocker used to treat acid-related disorders.

Aim

To compare tegoprazan 25 mg with lansoprazole 15 mg as maintenance therapy in healed erosive oesophagitis (EE) METHODS: In this phase 3, double-blind, multi-centre study, patients with endoscopically confirmed healed EE were randomised 1:1 to receive tegoprazan 25 mg or lansoprazole 15 mg once daily for up to 24 weeks. The primary efficacy endpoint was the endoscopic remission rate after 24 weeks. The secondary efficacy endpoint was the endoscopic remission rate after 12 weeks. Safety endpoints included adverse events, clinical laboratory results and serum gastrin and pepsinogen I/II levels.

Results

We randomised patients to tegoprazan 25 mg (n = 174) or lanso

SUBMITTER: Cho YK 

PROVIDER: S-EPMC10092320 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature